Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ883MR)

This product GTTS-WQ883MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ883MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12903MR IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OTSA101-DTPA
GTTS-WQ11047MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MCLA-128
GTTS-WQ12287MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ7533MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GC-182
GTTS-WQ11765MR IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MK-1308
GTTS-WQ7161MR IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FG-3019
GTTS-WQ13301MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-06523435
GTTS-WQ8605MR IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HuM195
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW